Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
Top Research Reports for Mastercard, Disney & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Disney (DIS) and Abbott (ABT).
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $77.54 in the latest trading session, marking a +1.85% move from the prior day.
Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
by Zacks Equity Research
We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.
Abbott (ABT) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $75.67, marking a -0.05% move from the previous day.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $75.64, marking a -0.81% move from the previous day.
Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
by Zacks Equity Research
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Abbott (ABT) and Illinois Tool Works (ITW).
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.